3.Potential applications of beta-elemene in anti-atherosclerosis and anti-restenosis.
Qinglei DONG ; Tieying YIN ; Guixue WANG
Journal of Biomedical Engineering 2013;30(3):656-660
It is well known that beta-elemene is a broadly effective antitumor drug. In recent years, many studies suggested that beta-elemene also has potential value in the treatment of atherosclerosis and restenosis. In this paper, the effect of beta-elemene in inhibition of angiogenesis, inhibition of thrombus formation, improvement of hemorheology, protection against oxidative injuries, anti-inflammation and suppression of restenosis after percutaneous transluminal coronary angioplasty (PTCA) are summarized and reviewed.
Anti-Inflammatory Agents
;
pharmacology
;
Antioxidants
;
pharmacology
;
Atherosclerosis
;
prevention & control
;
Coronary Restenosis
;
prevention & control
;
Humans
;
Sesquiterpenes
;
pharmacology
6.Chinese expert consensus on non-traditional blood lipid parameters to control the risks of arteriosclerotic cardiovascular disease.
Chinese Journal of Preventive Medicine 2022;56(4):405-421
Atherosclerotic cardiovascular disease is the general name of a series of diseases based on atherosclerosis. With the development of the social economy and the progress of population aging in China, the burden of atherosclerotic cardiovascular disease is increasing. However, in recent years some clinical studies have proved that the traditional blood lipid indicators, including low-density lipoprotein cholesterol, have some limitations in the risk control of atherosclerotic cardiovascular disease, and the blood lipid indicators need to be further supplemented and improved. This consensus expounds non-traditional blood lipid indexes from the perspectives of test and clinic, mainly including apolipoprotein B and lipoprotein a, non-high density lipoprotein cholesterol and lipoprotein residue, and non-fasting blood lipid. This consensus systematically expounds the pathophysiological mechanism of non-traditional blood lipid indexes, the relationship with cardiovascular disease, detection methods and performance, intervention, control and application in the state of cardiovascular disease, and gives the corresponding clinical expert suggestion.
Atherosclerosis/prevention & control*
;
Cardiovascular Diseases/prevention & control*
;
Consensus
;
Humans
;
Lipids
;
Lipoproteins
;
Risk Factors
7.Consensus standpoints from expert panel of Chinese Society of Cardiology on AHA/ACC 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults.
Xiaowei YAN ; Hong CHEN ; Wei GAO ; Jianjun LI ; Xinchun YANG ; Ping YE ; Shuyang ZHANG ; Dong ZHAO ; Jianhua ZHU ; Yong HUO
Chinese Journal of Cardiology 2014;42(4):275-276
8.Pharmacological Secondary Prevention of Ischemic Stroke.
Brain & Neurorehabilitation 2014;7(2):76-85
The causes of ischemic stroke are widely diverse, ranging from large artery atherosclerosis to cardioembolism, and it is important to use preventive therapy toward the goal reducing the future risk of recurrent ischemic stroke, myocardial infarction, and vascular death. Antithrombotic therapy is one of the fundamental medical approaches for secondary prevention of ischemic stroke, which is broadly divided into two general categories, those that exert their effect via platelet inhibition (antiplatelet agents), and those that influence various factors in the clotting cascade (anticoagulants). In general, the clinical guidelines recommend antiplatelet agents for patients with non-cardioembolic stroke, while anticoagulants is indicated for patients with presumed or proven cardioembolic stroke. Many clinical trials have attempted to test the efficacy and safety of antithrombotics in ischemic stroke. This review will discuss on currently available antithrombotic agents that have demonstrated efficacy for secondary prevention of ischemic stroke.
Anticoagulants
;
Arteries
;
Atherosclerosis
;
Blood Platelets
;
Fibrinolytic Agents
;
Humans
;
Myocardial Infarction
;
Platelet Aggregation Inhibitors
;
Secondary Prevention*
;
Stroke*
9.Inspection on advantage and cut-in point of integrative Chinese and Western medicine from view of cognitive transition on atherosclerosis.
Chinese Journal of Integrated Traditional and Western Medicine 2007;27(1):5-7
How to prevent and cure atherosclerosis (AS), reduce the occurrence and mortality of cardiovascular and cerebrovascular events is one of the hotspots in modern medicine researches. The understanding of AS experiences several dramatic transitions along with the deepening of researches, that is, from focusing on "vascular stenosis" to stressing "vulnerable plaque"; from taking the theory of "lipid deposit" as dominant to public acceptance of "inflammatory reaction" theory, and from "vulnerable plaque" to the new conception of "vulnerable patients". These changes bring forth the update concept and method of therapeutics, and also provide new opportunity and cut-in point for integrative Chinese and Western medicine in preventing and curing acute cardiovascular events.
Atherosclerosis
;
drug therapy
;
therapy
;
Drugs, Chinese Herbal
;
therapeutic use
;
Humans
;
Myocardial Infarction
;
prevention & control
;
Phytotherapy
;
methods
Result Analysis
Print
Save
E-mail